Download MendeleyCovalent PPAR gamma inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR gamma /RXR alpha-activated urothelial carcinoma.
Stuckey, J.I., Mertz, J.A., Wilson, J.E., Williamson, K.E., Li, Y., Kuljanin, M., Setser, J.W., DeLaBarre, B., Chenail, G., Nguyen, P.A., Scott, M.E., Geier, M.J., Bailey, C.M., Motley, W.W., Audia, J.E., Sims 3rd, R.J.(2026) Cell Chem Biol 33: 837-847.e14
- PubMed: 42208535 Search on PubMed
- DOI: https://doi.org/10.1016/j.chembiol.2026.04.017
- Primary Citation Related Structures:
9OLC - PubMed Abstract:
We investigated the conformational mechanisms underlying PPARγ activation in muscle-invasive urothelial carcinoma (MIUC) and sought to develop covalent inverse agonists to therapeutically reinforce a repressive state. The integration of mutational, structural, and biochemical analyses of PPARγ and RXRα guided the discovery of FX-909, a first-in-class clinical PPARγ inverse agonist that enforces a repressive conformational state, even in highly activated biological contexts. FX-909 is a potent, highly selective, and powerful suppressor of PPARγ transcriptional activity through the enhancement of PPARγ-nuclear co-repressor (NCOR) binding affinity. Treatment with FX-909 resulted in selective growth inhibition in PPARγ-activated MIUC cell lines and durable regressions in xenograft models of MIUC. FX-909 is capable of recapitulating PPARG genetic knockout phenotypes in vivo and is currently in clinical development for the treatment of intractable MIUC.
- Flare Therapeutics Inc. 400 Technology Square Suite 501, Cambridge, MA 02139, USA. Electronic address: jstuckey@flaretx.com.
Organizational Affiliation:
